LONDON, UK / ACCESSWIRE / June 23, 2019 / Kazia Therapeutics (ASX: KZA) has identified a higher maximum tolerated dose (MTD) from a Phase IIa study of its brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor GDC-0084 in glioblastoma (GBM), which may lead to improved efficacy in the ongoing expansion cohort and planned Phase IIb study. A new collaboration with the Alliance for Clinical Trials in Oncology (Alliance) means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers. It also expects further preliminary efficacy data from its Cantrixil Phase I study in ovarian cancer in H219. We adjust our valuation to between $64m and $103m.
We adjust our indicative valuation range to $64-103m or $10.27-16.50/ADR (vs $64-111m, $10.31-17.82/ADR), due to revised timelines for post-Phase III approval or single-pivotal-study approval scenarios for GDC-0084. Kazia had $4.1m cash at 31 December 2018 and will likely need to raise funds in H219. We estimate ~$11-15m will be needed to fully fund the GDC-0084 Phase IIb study.
Click here to view the full report.
Subscribe to Edison’s content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Dr Dennis Hulme, +61 (0)2 8249 8345
Dr John Savin MBA, +44 (0)20 3077 5735
SOURCE: Edison Investment Research Limited
View source version on accesswire.com: